Pfizer/BioNTech say final results show vaccine 95% effective
An illustration picture shows vials with Covid-19 Vaccine stickers attached and syringes with the logo of US pharmaceutical company Pfizer and German partner BioNTech, on November 17, 2020.
AFP/JUSTIN TALLIS
Pfizer/BioNTech say final results show vaccine 95% effective
(Agence France-Presse) - November 18, 2020 - 9:19pm

WASHINGTON, United States — Pfizer and BioNTech said Wednesday that a completed study of their experimental Covid-19 vaccine showed it was 95% effective.

They said the two-dose vaccine had no serious safety concerns and that the companies will apply for emergency use authorization from US regulators "within days."

The announcement came as coronavirus cases are surging in the US and other parts of the world, and boosted hopes for an end to the pandemic that has upended life around the globe.

"The study results mark an important step in this historic eight-month journey to bring forward a vaccine capable of helping to end this devastating pandemic," said Pfizer CEO Albert Bourla.

"With hundreds of thousands of people around the globe infected every day, we urgently need to get a safe and effective vaccine to the world," he added.

Pfizer had said last week after a preliminary analysis that its product was more than 90 percent effective.

On Monday another biotech firm involved in the race to develop a vaccine, Moderna, said its own vaccine was 94.5 percent effective, according to a preliminary analysis.

Pfizer has previously said it expected to contact the US Food and Drug Administration to apply for an Emergency Use Authorization by the third week of November.

The FDA had imposed a requirement on COVID-19 vaccine makers of having at least two months of follow-up with volunteers after their second dose, taken 28 days after the first, in order to ensure the drugs are safe.

Moderna developed its vaccine along with the US National Institutes for Health.

Both vaccines use mRNA (messenger ribonucleic acid) technology to deliver genetic material to the body that makes human cells create a protein from the virus.

This trains the immune system to be ready to attack if it encounters SARS-CoV-2.

Other vaccines that are in late-stage trials, such as one being developed by Johnson & Johnson and another by Oxford University and AstraZeneca, use modified viruses to deliver genetic material for the same purpose.

No mRNA vaccines have ever been approved, but Anthony Fauci, the United States' top infectious disease scientist, told AFP Tuesday the technology had now "established itself."

COVID-19 VACCINES NOVEL CORONAVIRUS PFIZER
As It Happens
LATEST UPDATE: November 25, 2020 - 10:47am

Pharma giants Sanofi and GSK said on July 29, 2020, that they have agreed to supply Britain with up to 60 million doses of a potential COVID-19 vaccine. The agreement covers a vaccine candidate developed by France's Sanofi in partnership with the UK's GSK and is subject to a "final contract."

This thread collects some of the major developments in the search for a vaccine to ease the new coronavirus pandemic. (Main photo by AFP/Joel Saget)

November 25, 2020 - 10:47am

The United States plans to distribute 6.4 million doses of the Pfizer-BioNTech COVID-19 vaccine in the first week after it is cleared for emergency use, which is likely next month, officials say Tuesday.

A committee of the Food and Drug Administration meets on December 10 to decide whether to green light the medicine, with the US confronted by soaring numbers of deaths and new cases.

Latest figures on Tuesday showed that the country had recorded a total of 259,600 COVID deaths and 12.5 million cases — with over 2,000 deaths and 167,000 new cases in just the last 24 hours.

General Gustave Perna, chief operations officer for the government's Operation Warp Speed, told reporters some 40 million doses of vaccine would be available by the end of December.

That figure includes another vaccine developed by Moderna and the National Institutes for Health, which announced some preliminary efficacy results last week and is also close to applying for emergency approval. — AFP

November 25, 2020 - 10:33am

The United States plans to distribute 6.4 million doses of the Pfizer-BioNTech COVID-19 vaccine in the first week after it is cleared for emergency use, which is likely next month, officials say.

A committee of the Food and Drug Administration meets on December 10 to decide whether to green light the medicine, with the US confronted by soaring numbers of deaths and new cases. — AFP 

November 24, 2020 - 6:48pm

Russia's Sputnik V coronavirus vaccine is 95% effective according to a second interim analysis of clinical trial data, its developers said on Tuesday.

The calculations were based on preliminary data obtained 42 days after the first dose, Russia's health ministry, the state-run Gamaleya research centre and the Russian Direct Investment Fund (RDIF) said in a statement. 

They did not note the number of cases used to make the calculation, however. — AFP

November 23, 2020 - 5:20pm

European stock markets opened firmer Monday, buoyed as positive news on another coronavirus vaccine trial helped offset concerns over soaring case numbers, dealers said.

In London, the FTSE 100 index of leading shares was up 0.5 percent at 6,382.36 points.

In the Eurozone, the Paris CAC 40 gained nearly one percent to 5,543.83 points and the Frankfurt DAX put on 0.6 percent to 13,219.25 points.

Shortly before the markets opened, British drugs group AstraZeneca and the University of Oxford said their jointly-developed vaccine against COVID-19 has shown "an average efficacy of 70 percent" in trials, and up to 90 percent in one dosage combination. — AFP

November 23, 2020 - 10:34am

The United States hopes to begin coronavirus vaccinations in early December, a top government health official said Sunday, the latest positive news to emerge even as cases surge across the worst-hit nation and elsewhere around the globe.

The beginning of vaccinations could be a crucial shift in the battle against a virus that has claimed more than 1.4 million lives worldwide, including 255,000 just in the US, since emerging from China late last year.

Encouraging results from vaccine trials have bolstered hopes for an end to the pandemic, as nations reimpose restrictions and lockdowns that slowed the spread earlier this year but turned lives and economies upside down across the globe. — AFP

Philstar
  • Latest
Latest
Are you sure you want to log out?
X
Login

Philstar.com is one of the most vibrant, opinionated, discerning communities of readers on cyberspace. With your meaningful insights, help shape the stories that can shape the country. Sign up now!

FORGOT PASSWORD?
SIGN IN
or sign in with